Invitae Corp
Change company Symbol lookup
Select an option...
NVTA Invitae Corp
BAC Bank of America Corp
KVHI KVH Industries Inc
BHC Bausch Health Companies Inc
ANPC AnPac Bio-Medical Science Co Ltd
TREX Trex Company Inc
VIVO Meridian Bioscience Inc
WASH Washington Trust Bancorp Inc
AWF AllianceBernstein Global High Income Fund Inc.
AVK Advent Convertible & Income Fund
Go

Health Care : Biotechnology | Mid Cap Growth
Company profile

Invitae Corporation utilizes an integrated portfolio of laboratory processes, software tools and informatics capabilities to process deoxyribonucleic acid (DNA)-containing samples, analyze information about patient-specific genetic variation and generate test reports for clinicians and their patients. As of December 31, 2016, the Company's products consisted of assays totaling over 1,100 genes that could be used for multiple indications, including hereditary cancer, neurological disorders, cardiovascular disorders, pediatric disorders and other hereditary conditions. The Company offers panels for a range of hereditary conditions in cancer, cardiology, neuromuscular, pediatric and rare diseases. The Company focuses on genetic testing, genome network and genome management. The Company offers full gene sequencing and deletion/duplication analysis as a standard for all of its tests. The Company holds interests in AltaVoice, a patient-centered data company.

Price
Delayed
$45.26
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
--
Day's Low
--
Volume
(Light)

Today's volume of 1,651 shares is on pace to be much lighter than NVTA's 10-day average volume of 2,659,962 shares.

1,651

Display:

Providers:

UpdateCancel
6 providers
October 23, 2020
Invitae to Announce Third Quarter 2020 Financial Results on Thursday, November 5, 2020

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its third quarter 2020 financial results on Thursday, November 5, 2020 and will host a conference call and webcast that day at 4:30 p.m...(PR Newswire)

October 22, 2020
Invitae and Pacific Biosciences Collaborate to Develop Whole Genome Sequencing-Based Assays for Pediatric Epilepsy Diagnostics

Invitae Corporation (NYSE: NVTA), a leading genetics company, and Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced a research...(Globe Newswire)

October 08, 2020
New Study Finds Germline Genetic Testing Detects Actionable Findings Missed by Tumor-only Sequencing

Tumor-only genetic sequencing misses medically actionable genetic variants in cancer patients that germline genetic tests identify, according to a new study published this week in JAMA Network Open that included researchers from Invitae (NYSE...(PR Newswire)

October 05, 2020
Invitae Completes Transaction with ArcherDX to Bring Comprehensive Cancer Genetics and Precision Oncology to Patients Worldwide

Invitae Corporation (NYSE: NVTA), a leading genetics company, today announced that on October 2, 2020, it completed the transaction to bring ArcherDX, a leading genomics analysis company, into Invitae to create a comprehensive offering that provides...(PR Newswire)

September 11, 2020
Invitae Appoints Kimber Lockhart to its Board of Directors

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced the appointment of Kimber Lockhart to its Board of Directors, effective September 10, 2020. https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg (PR Newswire)

September 09, 2020
PTC Therapeutics Launches PTC PINPOINT - A Genetic Testing Program for Individuals Suspected of Having Neurotransmitter Disorders

PTC Therapeutics, Inc. (NASDAQ: PTCT) today introduced a new program that provides genetic testing and counseling for people who may have a neurotransmitter disorder, such as aromatic L-amino acid decarboxylase (AADC) deficiency. The program, called...(PR Newswire)

September 03, 2020
Multi-site study to evaluate the role of testing guidelines in ensuring access to genetic information for men with prostate cancer

Invitae (NYSE: NVTA), a leading medical genetics company, today announced enrollment has begun for a nationwide study to better understand the role of current genetic testing guidelines in ensuring prostate cancer patients receive testing to...(PR Newswire)

September 01, 2020
Invitae to Participate in the Morgan Stanley Virtual Global Healthcare Conference

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that members of its management team will virtually participate in a fireside chat at the 18th Annual Morgan Stanley Global Healthcare Conference on Monday...(PR Newswire)

August 26, 2020
Civilization Ventures Announces $35M Second Fund

Civilization Ventures is announcing the close of its second fund following the successful investment of Fund I in 2017, where the firm had major portfolio exits with the public listing of gene therapy leader Rocket Pharma (NASDAQ: RCKT) and the...(BusinessWire)

August 04, 2020
Invitae Reports Inducement Grants Under NYSE Rule 303A.08

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it granted restricted stock units ("RSUs") to Kenneth D. Knight, Invitae's new Chief Operating Officer and Karthik Suri, Invitae's new Chief Digital Officer...(PR Newswire)

Invitae Reports $46.2 Million in Revenue Driven by More Than 120,000 Samples Accessioned in the Second Quarter of 2020

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced financial and operating results for the second quarter ended June 30, 2020. https://mma.prnewswire.com/media/268592/invitae_corporation_logo.jpg (PR Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.